Sartorius Stedim Biotech presents annual report for 2021
Aubagne, February 17, 2022
Sartorius Stedim Biotech, a leading partner of the biopharma industry, today has presented its Universal Registration Document 2021 including the Annual Financial Report. Besides providing detailed information on its business performance, as well as on innovations, acquisitions and sustainability initiatives, the company also confirms its preliminary figures for fiscal 2021, which had already been published on January 27, 2022.
The company’s outlook for fiscal 2022, updated on February 8, was also confirmed. Accordingly, Group sales revenue is expected to increase by about 15 percent to 19 percent. This includes an expected non-organic growth contribution from acquisitions of about 2 percentage points. The company’s underlying EBITDA margin is forecasted to reach more than 35 percent. All figures for the forecast are based on constant currencies.
This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.